FREMONT, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- CoaguSense, Inc., a subsidiary of i-SENS (KOSDAQ:099190), today announced that it has received approval for the sale of the Coag-Sense ® PT/INR ...
FREMONT, Calif., April 2, 2019 /PRNewswire/ -- CoaguSense, Inc., a subsidiary of i-SENS (KOSDAQ:099190), announced today that the U.S. Food and Drug Administration (FDA) has cleared its ...
November 22, 2011 — Patients receiving long-term, steady-dose warfarin therapy who have had stable international normalized ratios (INRs) for at least 6 months can safely go 12 weeks between dose ...
(HealthDay News) — For hospitalized patients, international normalized ratio (INR) monitoring less frequently than daily is associated with increased odds of warfarin-associated adverse events, ...
The Coag-Sense® PT/INR Monitoring System is based on the same mechanical principle as the World Health Organization’s gold standard manual tilt-tube technique (MTT), used to this day for calibration ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback